Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Nausea was the primary adverse event, occurring in 67% of participants at the highest dose but predominantly mild-to-moderate in severity
Nonetheless, clinicians should remain vigilant for unexplained BP rises
While it's essential to recognize that the FDA does not endorse off-label use, the demand for Ozempics weight loss magic couldn't be ignored, leading to practitioners across the country taking the obesity fight into their own handsor prescription pads
Kailera IPO'd in 2025 with HRS9531 (dual GLP-1/GIP, Phase 3 China readout ~17.7% weight loss February 2026) as its lead asset and HRS-4729 (the triple agonist) as an earlier-stage follow-on
US$ 22.62
US$ 21.77
US$ 24.19
US$ 27.70
